Shots:

• The P-III PANORAMA Trial involves assessing of Eylea (aflibercept) vs sham injection in 402 patients with moderately severe to severe NPDR in without DME for 16 wks. or 8 wks.
• P-III study results: Patients with ≥2‑step improvement on DRSS score (65%- 80% vs 15%); Patients who developed a vision-threatening event (10%- 11% vs 41%); patients with severe non-proliferative diabetic retinopathy (NPDR) (15%- 15% vs 53%); Subgroup with moderately severe NPDR (8%- 10%- vs 36%)
• Eylea (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor- indicated for Neovascular (Wet) AMD- Macular Edema RVO & DME- with expected PDUFA on 13 May- 2019 for DR

Ref: PRNewswire | Image: Limerick Leader